[SG] 7 Interesting Stock Ideas for March 2022

March 2022

The world has been mired in lots of economic uncertainty due to Russia’s invasion into Ukraine.

This has inadvertently caused a lot of blood shed, not only in Ukraine but also in the stock markets. With Nasdaq and S&P 500 index in correction regions, stocks all over the world were not spared.

That said, there are still 7 stocks that are bullish in Singapore which you can keep track for a tactical rebound.

#1 Centurion Corp

UOB Kay Hian has maintained its Buy rating on the stock with a target price of $0.45.

The good results as well as potential recovery due to countries opening up are main causes of the positive analysis.

“Centurion Corp (Centurion) reported 2021 revenue of S$143m (+11% yoy) and PATMI of nearly S$53m, triple that of 2020 and exceeded our estimates.

The large increase at the bottom line was the result of a fair value gain on investment properties of S$11.4m in 2H21 (mostly relating to UK assets) vs a loss of S$27.6m in 2H20.

Centurion’s 2H21 revenue and gross profit rose 21% and 17% hoh respectively, driven by both an expansion in portfolio capacity in Singapore and Malaysia as well as a steady recovery of occupancy rate in its purpose-built student accomodation (PBSA) in the UK.

Looking back to the start of COVID19 in 1H20, the company’s revenue and gross profit has clearly troughed in 2H20.

In our view, Centurion’s profitability and business prospects should continue its pace of recovery in 2022.”

>> Read more about the company here.

#2 Singapore Medical Group

UOB Kay Hian has maintained its Buy rating on the company with a target price of $0.53.

Better than expected results and healthy balance sheet are driving the sentiments of the analyst.

“Singapore Medical Group (SMG) reported record-high revenue (+15.5% yoy, +6.5% yoy vs 2019) and net profit (+78.8% yoy, +14.3% yoy vs 2019) for 2021, forming 108.0% and 112.1% of our full-year estimates respectively.

A final dividend of 0.65 S cents (0.4 S cents in 2020) was declared along with a special dividend of 0.25 S cents, implying a payout ratio of 25% of 2021’s earnings.

With strong core business operations cash flows of S$24.4m, the group improved its net cash position to S$22.9m (2020: S$15.8m). Gearing ratio also fell to 2.2% from 6.4% in 2020.

We reckon that the group is in strong position to continue its organic growth in Singapore as well as to expand in overseas markets which management has earmarked as SMG’s next revenue growth driver”

>> Read more about the company here.

#3 Hong Leong Asia

CGS CIMB has maintained its Add rating on the company with a target price of $1.00.

Sequential recovery from its unit and construction rebound in Singapore are bound to help the company.

“Building materials unit (BMU) recorded 2H21 PBT of S$19m (+19% yoy), supported by rising demand for concrete products in Singapore as construction activity recovers.

The Building and Construction Authority (BCA) expects further demand recovery for building materials in Singapore in CY22F.

[It also] forecasts industry-ready mixed concrete demand to grow 8-21% and precast concrete demand to grow 45-63%.

We forecast HLA’s building materials segment to see PBT growth of 27% yoy in FY22F, riding on 1) stronger sales volume in Singapore, 2) narrower Tasek losses, and 3) higher profit contribution from associate BRC Asia.

Commercialisation of HLA’s integrated construction and prefabrication hub (ICPH) in 4Q22F could further boost segment earnings in FY23F”

>> Read more about the company here.

#4 Sembcorp Industries

Phillips Capital has upgraded the company to Accumulate rating on the stock with a target price of $2.940.

Impressive results and more than healthy cash flow are driving the valuation.

“FY21 net profit of $300mn was above our estimates, at 146% of FY21e. The beat came from higher revenue from Conventional Energy, which surpassed our expectations on the back of better spark and dark spreads particularly in 4Q21.

The better spreads arose from stronger commodity price and better demand-supply dynamics.

Net profit before exceptional items was 69% higher YoY, lifted by higher contributions from all key revenue segments:

  • Renewables
  • Integrated Urban Solutions and
  • Conventional Energy

Its coal business in India – Thermal Power Project I (P1) and Thermal Power Project II (P2) – also performed better than expected with higher demand lifting turnover.

This segment remained the key contributor to turnover, accounting for 84% of overall revenue.

Net gearing declined by more than 20% of our FY21e forecast. Free cash flow rose 71% YoY as better operating performance drove higher net cash from operating activities.

The repayment of its project finance debt for Sembcorp Energy India and Sembcorp Green Infra drove net gearing lower to 160.8% from 199.8% in the same period last year.”

>> Read more about the company here.

#5 UMS Holding Ltd

CGS CIMB has maintained its Add rating on the stock and with its target price at $1.63.

Positive outlook from the management and order book bodes well for the company.

“UMS has guided for strong orders given that its key customer continued to provide positive guidance for FY22F. According to the World Semiconductor Trade Statistics (WSTS), global semiconductor sales are set to grow by 8.8% in 2022, to US$601bn.

Management said UMS’s new Penang factory, which is scheduled for completion by endFY22F, will increase its current production capacity substantially.

[It will also] position the group to take on new orders from potential new customers which are expanding in Southeast Asia”

>> Read more about the company here.

#6 Frencken Group

UOB Kay Hian has maintained its BUY rating on the company with a target price of $6.94.

With semi-conductor being a clear growth driver, it will help the company on its other slowing down segments.

“Frencken Group’s (Frencken) 2H21 revenue of S$391.8m (+19.4% yoy, +4.4% hoh) brought 2021 revenue to S$767.1m (+23.6%).

For the year, this was led by positive contributions from the semiconductor (+51.5%), medical (+26.4%) and analytical & life sciences (+25.3%) sub-segments, but was partially offset by industrial automation (-15.9%) and automotive (-15.9%)

Relative to 2H21, sales guidance is anticipated to be better for semiconductor, industrial automation and automotive sub-segments, while medical and analytical & life sciences sub-segments will be stable on a hoh basis.”

>> Read more about the company here.

#7 Hyphens Pharma International

CGS CIMB has maintained its Add rating on the company with a target price of $0.36.

Astute acquisition of new company is likely going to help with the bottom line of the company.

“FY21 revenue and core profit was in line at 99%/103% of our estimates. HYP completed the acquisition of Novem by end-FY21, ahead of our expected end-FY22F. This implies that Novem’s full FY22F earnings will be reflected in HYP’s books.

We expect Novem to contribute c.S$1.5m (c.22% of FY21 net profit) to HYP’s FY22F bottomline.

Based on Novem’s FY18-20 net profit of S$1.5m-2m, which would be partially offset by finance costs and goodwill amortisation in relation to the acquisition.

HYP’s inventory days jumped to 118 days in FY21 (vs. 80 days in FY20) because Novem’s books were consolidated in their entirety in FY21 despite only contributing a month’s worth of revenue.

Management guided that Novem tends to keep six months’ worth of inventory as Novem’s tender contracts with restructured hospitals typically require them to keep at least five months’ worth of stock on hand.

We thus adjust FY22F inventory days to 107 days.”

>> Read more about the company here.

Billionaire Warren Buffett is arguably the most successful investor of all time.

Learn the secrets to Warren Buffett’s investment success by downloading the Free Guide below:

Download FREE Guide – Warren Buffett’s 12 Secrets.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}
Subscribe to get the latest updates
>